CBIH · Cannabis Bioscience International Holdings, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“As indicated in Note 3 of the notes to the audited consolidated financial statements for the period ended February 28, 2026, and the report thereon of the Company's independent auditing firm, there is substantial doubt as to the ability of the Company to continue as a going concern.”View the 10-Q filed Apr 16, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| $123.63K | $303.02K | $248.84K | $316.83K | |
| $26.23K | $40.11K | $45.6K | $93.45K | |
| $97.39K | $262.92K | $203.24K | $223.38K | |
| — | 86.76% | 81.68% | 70.5% | |
| $31.42K | $101.91K | $123.76K | $177.11K | |
| $496.21K | $684.28K | $689.38K | $1.21M | |
| -$398.82K | -$421.37K | -$486.14K | -$983.37K | |
| — | -139.05% | -195.36% | -310.38% | |
| $148.75K | $136.26K | $154.21K | $90.97K | |
| -$116.47K | -$127.46K | -$165.21K | -$49.21K | |
| — | — | $0 | $0 | |
| -$515.29K | -$548.82K | -$651.35K | -$1.03M | |
| — | -181.12% | -261.75% | -325.91% | |
| USD/shares | -$0.00 | -$0.00 | -$0.00 | -$0.00 |
| USD/shares | -$0.00 | -$0.00 | -$0.00 | -$0.00 |
| shares | — | 10.72B | 10.32B | 9B |
| shares | — | 10.72B | 10.32B | 9B |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Long-term debt, including current maturities | 2026-02-28 | USD 290,865 | 10-Q filed 2026-04-16 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Operating lease liabilities | 2026-02-28 | USD 0 | 10-Q filed 2026-04-16 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 21 similar-size Drug Manufacturers - Specialty & Generic companies (of 101 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Clinical Trials | $301,731 | $213,865 | $267,220 |
| Merchandise | $1,291 | $4,410 | $22,300 |
| Consulting Fees | $0 | $28,641 | $8,333 |
| Seminar Fees | $0 | $1,925 | $16,433 |
| Video Course | — | — | $2,497 |
| Royalty | — | — | $42 |